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Abstract 
Background: Laser-assisted photodynamic therapy is being explored as a method to enhance 
efficacy of photodynamic therapy (PDT).  
Objective: To compare a continuous (CL) and a fractional (FL) ablative CO2 laser-assisted 
methyl aminolevulinate PDT in the management of superficial basal cell carcinoma (sBCC) 
and Bowen’s Disease (BD). 
Methods: Thirty treatment areas in fifteen patients with inoperable, histologically verified 
sBCC or BD, received CL or FL after intra-patient randomisation. Laser treatment was 
followed by MAL application and illumination occurred 3 hours later. This treatment was 
repeated after two weeks. An equivalence analysis was performed on the primary endpoint 
efficacy, while secondary endpoints pain, side effects and aesthetics were evaluated using 
paired samples tests. Patients were also asked for their preferred treatment.  
Results: An excellent efficacy of 92,9% (sBCC, 100%; BD, 80%) was found in both CL+PDT and 
FL+PDT after 12 months. Equivalence could not be established. Little pain was perceived in 
most patients during and immediately after PDT illumination. PDT treatment in FL+PDT was 
less painful, significantly during the second treatment (P=0,026). Side effects were mild to 
moderate with erythema being the most frequent immediate side effect, followed by 
oedema, crusting and burning sensation. Pigmentary changes occurred in 21% (CL+PDT) to 
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29% (FL+PDT) and aesthetics were good to excellent in all patients. CL+PDT and FL+PDT did 
not significantly differ in side effects (P=0,219-1,000) or aesthetics (P=0,157-1,000). 
Conclusions: Results in this pilot study support the promising role of laser-assisted PDT. Both 
treatment arms demonstrated the same efficacy as well as comparable side effects and 
aesthetics. PDT illumination was significantly less painful in the FL+PDT group, suggesting a 
preference for FL+PDT. The authors recommend further investigation with a larger sample 
size, a subgroup analysis between sBCC and BD and comparison of different treatment 
protocols before one technique could be preferred to another. 
  
Introduction 
Non-melanoma skin cancer (NMSC) is the most frequent skin tumour in the Caucasian population1, 
for which surgical excision is the golden therapeutic standard. Superficial basal cell carcinoma (sBCC) 
and squamous cell carcinoma in situ or Bowen’s Disease (BD) are two superficial types of NMSC 
whose diagnosis tends to be delayed because they present asymptomatically and often mimic benign 
skin conditions such as eczema. Frequently, these tumours present as large or multiple lesions on 
cosmetic sensitive areas. In this case, physicians may consider laser ablation, electrodessication and 
curettage, cryotherapy, radiotherapy or topical non-invasive strategies such as photodynamic 
therapy (PDT) with methyl aminolevulinate (MAL), 5-fluorouracil (5-FU) or imiquimod as alternatives 
to surgery1,2. Cryotherapy and electrodessication combined with curettage are simple and 
inexpensive treatments for low-risk tumours, but should be avoided on cosmetic sensitive areas3,4. 
Despite limited evidence in literature, tumour ablation with a carbon dioxide (CO2) laser is a 
convenient treatment option for sBCC and BD in patients with multiple or recurrent tumours or with 
lesions on anatomical challenging treatment sites5–7. PDT, 5-FU and imiquimod generally result in 
good cosmetics8–10, however, recurrence following topical therapies is well known to be high 
compared to surgery11,12. While PDT is an office-based procedure, efficacy of 5-FU and imiquimod is 
dependent on patient compliance3,4.  
 
The concept of laser-assisted PDT has increasingly been studied as an extension of the therapeutic 
arsenal for managing NMSC. Ablative laser pretreatment disrupts the stratum corneum, an 
important physical skin barrier. Additionally, the laser on its own adds therapeutic effect. Several 
preclinical studies showed facilitated accumulation of topically applied drugs13–16. Clinical studies 
demonstrated enhanced lesion response when CO2 or Erbium-doped Yttrium Aluminium Garnet 
(Er:YAG) laser preceded PDT compared to PDT or laser alone2,17–25. Ablative laser-assisted PDT is 
considered to offer good tolerability, satisfactory aesthetics and might provide other advantages 
such as reduced photosensitizer incubation time18,25,26. 
 
Both continuous ablative and fractional ablative laser devices have been explored13,15,27. Whereas 
continuous ablative lasers (CL) reduce tumoural thickness by ablating the epidermis in a continuous 
manner, fractional ablative laser devices (FL) create microscopic vertical channels of ablation 
surrounded by a coagulated cuff, referred to as microscopic treatment zones. These zones facilitate 
penetration of topical molecules. The surrounding tissue is relatively spared, resulting in better 
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wound healing27. An ex vivo study on porcine skin found both continuous and fractional ablative laser 
settings capable of enhancing PDT fluorescence intensities, with higher intensities observed after 
continuous ablation13. Since CL is a treatment strategy on its own, it can be argued that CL 
pretreatment implies better efficacy compared to FL. The tissue-sparing effects of fractional laser 
technology, however, might possibly translate into less side effects and better aesthetics compared 
to CL+PDT. To the best of our knowledge, this randomised controlled trial is the first to make a direct 
comparison between MAL-PDT pretreatment with CL (CL+PDT) and FL (FL+PDT) for managing sBCC 
and BD. During a twelve-month follow-up, this study investigates if CL+PDT and FL+PDT provide an 
equivalent efficacy, and if differences in pain, side effects, aesthetics and patients’ preference can be 
observed.  
 
Materials and methods 
Inclusion, blinding and randomisation 
This randomised controlled pilot study was approved by the Ethics Committee of Ghent University 
Hospital, Belgium, on September 1th 2014 and was performed in accordance with the Helsinki 
declaration. The trial was registered in the U.S. National Institutes of Health clinicaltrials.gov 
database (identifier: NCT03012009). All patients were recruited in the dermatological department of 
Ghent University between January 2015 and March 2016. An informed consent was signed prior to 
inclusion. Eligible patients had a histologically proven and inoperable sBCC or BD with a size larger 
than 5 cm2 or had two smaller lesions. Inoperability was implied by characteristics of the tumour 
(size, localisation) and/or the patient (age, use of anticoagulants). Large lesions were subdivided into 
two treatment areas to make intra-patient comparison possible. Exclusion criteria were pregnancy or 
lactation, age below 18, history of an allergic reaction to local anaesthesia and history of side effects 
related to laser or PDT. Every patient received a personal number to guarantee anonymity. Prior to 
treatment, within-subject randomisation with sealed envelopes randomly assigned every treatment 
area per patient to receive CL+PDT or FL+PDT.  
 
Treatment protocol 
After local anaesthesia by means of a subcutaneous injection with 1 to 2,5 ml of lidocaine 
hydrochloride 2% with epinephrine (AstraZeneca, United Kingdom) per treatment area, half of the 
treatment areas was pretreated with CL and the other half with FL according to within-subject 
randomisation. The MiXto SX® Slim Evolution CO2 laser (Lasering s.r.l., Modena, Italy) with 8 ms pulse 
duration treated clinical visible lesion with CL (12 W power, to the level of the papillary dermis) or FL 
(30 W power, 15% density, 180 μm spot size, 240 mJ energy, 943 J/cm2 fluency). Ferric chloride 20% 
was used in case of bleeding. A 1 mm thick layer of MAL 16% (Metvix®, Galderma, Lausanne, 
Switzerland) was applied under occlusion and after 3 hours, lesions were illuminated with a red light-
emitting diode at 37 J/cm2 (Aktilite® CL128, Galderma, Lausanne, Switzerland). PDT pain 
management was administered according to patients’ wishes through optional intake of paracetamol 
500 mg half an hour before illumination and by spraying cold water during illumination. Finally, 
wound care was executed using Fucidin® 2% ointment (Leo, Ballerup, Denmark) covered with 
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Cosmopor E® (Hartmann, Heidenheim, Germany). Eau Thermale Avène Gel Anti-Brûlures (Pierre 
Fabre, Laboratoires Dermatologiques Avène, Boulogne, France) was used in case of burning 
sensation. This treatment modality was repeated after two weeks (Fig. 1). 
 
Study protocol 
The study protocol is summarized in Table 1. Histological assessment by means of punch biopsy 
occurred prior to treatment. Clinical visible tumour borders were marked on plastic templates in 
order to help the investigators identify the treatment areas during follow-up. A telephonic survey 
was held one week after every treatment session and follow-up visits were provided 3, 6 and 12 
months after treatment. A blinded expert, who was always the same person and never the treating 
investigator, assessed clinically and in person the primary endpoint efficacy during the follow-up 
visits using a 3-point scale with complete regression (CR), partial regression (PR) and no regression 
(NR) defined as a regression percentage of respectively 100%, 25-99% and 0-24%. The clinical 
efficacy was verified histologically at the end of follow-up by means of a punch biopsy taken in the 
middle of each treatment area or at a location clinically suspicious for recurrence. Histological 
evaluation was performed blinded at the Pathology Department of Ghent University Hospital. 
Patients scored pain perceived during PDT illumination on a Visual Analogue Scale (VAS) of 100 mm. 
Side effects (erythema, oedema, crusting, burning sensation, pain, vesicles, hematoma, infection, 
pigmentary changes (hypo- or hyperpigmentation) and scarring) were assessed immediately after 
PDT, during the telephonic survey one week post-treatment, before the second treatment session 
and at every follow-up visit. Aesthetics were scored by both the blinded expert and patient using a 
four-point scale (excellent: no significant changes – good: minor changes – poor: serious hypo- or 
hyperpigmentation and/or visible scarring – very poor: important scarring). Patients were asked for 
their preferred treatment option during every follow-up visit and for factors influencing this 
preference (efficacy, pain, side effects or aesthetics).  
 
Statistical analysis  
On the assumption that both CL+PDT and FL+PDT imply an improvement of PDT in monotherapy, 
high efficacies in both treatment arms were expected. Therefore, the authors decided that an 
equivalence analysis on the primary endpoint efficacy would be the most meaningful choice. 
Equivalence analysis was performed with the ‘Tango’s score confidence interval for a difference of 
proportions with matched pairs’ (α=0,025). The equivalence margin δ=16,1% was based on existing 
literature by computing the difference in a clinical assessed efficacy of 97,1% found for CL+PDT28 and 
of 81% for FL+PDT19. The chosen value of δ is a rough estimate since these studies treated nodular 
BCC (nBCC) or the broad spectrum of BCC and a δ value of 16% is rather substantial from a clinical 
viewpoint. Paired samples tests determined if a difference in the secondary endpoints (pain, side 
effects, aesthetics and patients’ preference) existed. Side effects and patients’ preference were 
analysed by means of the McNemar’s test (α=0,05). The Wilcoxon matched-pairs signed ranks test 
was used for the variable pain (α=0,05). Data were analysed using IBM® SPSS® Statistics Version 
22.029 and R version 3.3.230. We aimed to include at least 12 patients since a minimal sample size of 
12 patients per group is recommended for pilot studies31. 
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Results 
Patient characteristics 
Fifteen out of the 16 included patients with histologically proven sBCC (n=9) or BD (n=6) received 
study treatment. Two CL+PDT treatment areas, which were not sufficiently healed, received PDT only 
during the second treatment. One patient was loss to follow-up after 3 months because of health 
problems not related to the study treatment. Table 2 and Fig. 2 present an overview of the patients’ 
baseline characteristics and patient flow. 
Efficacy 
An overview of the efficacy during follow-up is summarized in Table 3. After 12 months, 92,9% 
(13/14) of patients in the intention-to-treat (ITT) group achieved clinical CR in both CL+PDT and 
FL+PDT, which was histologically confirmed. This equals a response of 100,0% (9/9) in the sBCC and 
80,0% (4/5) in the BD subgroup. No equivalence in efficacy could be established 3, 6 and 12 months 
after treatment (δ = [-0,161;0,161], respective 95% confidence interval = [-0,298;0,151], [-
0,315;0,159] and [-0,215;0,215]). Efficacy in the per protocol (PP) group equalled 91,7%. If a 
difference in clinical efficacy between CL+PDT and FL+PDT was noticed during follow-up, this was 
always in the advantage of FL+PDT. In one sBCC patient, a nodular component was detected on the 
skin biopsy. This patient was in CR after 12 months.  
Pain during PDT illumination 
In the FL+PDT group, less pain was observed during PDT illumination, which was not significant in the 
ITT analysis during the first treatment (P=0,144) but significant during the second treatment 
(P=0,026) (Fig. 3). The same trend can be noticed in the PP analysis (P=0,285 resp. P=0,039). During 
the first treatment, a median VAS-score of 5 mm was observed in both treatment arms, ranging 
between [0-74] in CL+PDT and [0-60] in FL+PDT. During the second treatment session, a median VAS-
score of 20 mm (range [0-85]) was observed in CL+PDT and a median VAS-score of 10 mm (range [0-
60]) in FL+PDT in both ITT and PP analyses. In general, most patients experienced treatment as little 
painful. During the first and second treatment respectively 73% (11/15) and 80% (12/15) of the 
patients scored less than 20 mm on the VAS-scale in both treatment areas.  
Side effects 
Table 4 gives an overview of the side effects identified during hospital visits. Side effects are not 
significantly different between CL+PDT and FL+PDT (P = 0,219-1,000). Erythema was the most 
frequently observed side effect immediately after both treatments (CL+PDT, 93%; FL+PDT, 87%). 
Prevalence of erythema decreased while continuing follow-up but remained present in 21% after 12 
months. Other frequently reported side effects were oedema, crusting, burning sensation, pain and 
pigmentary changes. Vesicles and infection were sporadically observed, hematoma never. During the 
telephonic survey one week after the first treatment session, crusting was reported equally as 
frequent in both treatment arms (36%), but was more pronounced in the FL+PDT group before the 
second treatment session was initiated (20% vs. 47%). Approximately one third of patients reported 
pain during the telephonic surveys one week post-treatment. No scars were present one year after 
treatment, but pigmentary changes were detected in 21% of the lesions treated with CL+PDT and 
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29% of those treated with FL+PDT.  
Aesthetic result 
No significant difference in aesthetics was found 3, 6 or 12 months post-treatment according to the 
patients and blinded expert (P=0,075-1,000). After 3 months, 86% of the patients considered 
aesthetics as good or excellent. On the other hand, the blinded investigator considered aesthetics as 
good to excellent in only 67% (CL+PDT) to 53% (FL+PDT) of the patients. After 6 months, aesthetics in 
CL+PDT and FL+PDT were overall considered to be better, with good to excellent aesthetics in 84% 
respectively 92% according to the patients and 85% respectively 78% according to the blinded 
investigator. After 12 months, aesthetics scored good to excellent in all areas. Patients scored 60% of 
CL+PDT and 80% of FL+PDT as excellent, while the blinded investigator scored 50% of CL+PDT and 
FL+PDT as excellent (Fig. 4). 
Technique of preference 
After 3 months, 21% (3/14) of the patients preferred CL+PDT, 7% (1/14) preferred FL+PDT and 71% 
(10/14) had no therapy preference. After 6 months, 10% (1/10) of the patients preferred CL+PDT, 
30% (3/10) preferred FL+PDT and 60% (6/10) had no preference. After 12 months, none of the 11 
patients preferred one treatment to another. Of the 9 patients who indicated the most important 
factor determining their treatment preference, 67% (6/9) appointed efficacy, 22% (2/9) aesthetics, 
11% (1/9) pain and 0% (0/9) side effects. 
 
Discussion  
Results in this study support the promising role of laser-assisted PDT. An excellent clinical and 
histological efficacy of 92,9% was seen in both CL+PDT and FL+PDT, but equivalence in efficacy could 
not be established. Mild to moderate side effects, outstanding aesthetics as well as little pain were 
observed, however, FL+PDT was considered less painful. This technique might be particularly useful 
for patients with surgical contraindications, in patients who refuse surgery, in whom surgery is 
challenging e.g. patients with large lesions on cosmetic sensitive areas or when self-application of 
topical therapy is difficult. 
Previous clinical studies in the field of ablative laser-assisted PDT for BCC or BD applied variable CO2 
or Er:YAG laser settings, varied in the number of treatment sessions and focussed on nBCC or a mix 
of BCC subtypes instead of sBCC. This has to be considered when comparing efficacy. Our study 
shows different efficacy in the 2 tumour subgroups. We found that all sBCC lesions responded to 
therapy. Previous studies found similarly high efficacy in CL+PDT for BCC, but results in FL+PDT are 
varying. Shokrollahi et al. observed 97,1% CR after one to three CL+PDT sessions in 177 BCC28. 
Smucler et al. found 99,0% CR in 194 recurring nBCC 12 months after CL+PDT and found good, 
however, lower efficacy after PDT (94,9% CR) and CO2 laser (91,8% CR)17. Haak et al. observed a low 
12-month histological efficacy in FL+PDT (63% CR), which was not significantly different from the 
one in PDT (56% CR) in 32 high risk nBCC19. On the other hand, a study of Choi et al. found 
significantly better efficacy after one session of FL+PDT (78,9% CR) compared to two sessions of PDT 
(22,2% CR) during a follow-up period of 12 months in 42 thin nBCC21. A study of Lippert et al. 
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observed a better 18-month efficacy after two sessions of FL+PDT (92,9% CR) than after PDT (80,4% 
CR) in 56 nBCC pretreated with a diode laser20. In BD, our study observes 80,0% CR, which is situated 
in between the results of previous studies. A RCT of Ko et al. found significantly higher efficacy after 
one session of FL+PDT (87,5% CR) compared to PDT (50,0% CR) in 58 BD25. Although Cai et al. found a 
similar response after one to three sessions of CL+PDT (72,73% CR; 8/11 BD) and CL (63,33% CR; 7/11 
BD), significantly higher recurrence was seen in the laser-only group after 6 months2. Summarized, 
previous studies found laser-assisted PDT in BCC and BD more effective than PDT or laser alone, 
except for one study about FL+PDT in high risk nBCC. 
Most patients experienced low pain levels during PDT illumination, which was performed 3 hours 
after subcutaneous injection of lidocaine hydrochloride 2% with epinephrine. Some of the patients 
probably still benefited from this anaesthesia during PDT illumination, regarding the fact that 
lidocaine 2% with epinephrine has an anaesthetic effect for 2 to 6 hours32. This, however, is no 
explanation for FL+PDT being perceived as less painful as intra-patient comparison was made. 
Previous studies using lidocaine-prilocaine 5% anaesthetic cream considered FL+PDT as painful as 
PDT, but observed higher mean VAS-scores (42,2-48,6 mm) compared to ours (10,0-20,33 mm)21,25. 
Observed side effects are similar to the known side effects of CO2 laser and PDT in monotherapy33–36. 
Previous studies about FL+PDT found a frequency of side effects comparable to those in this study, 
except for increased crusting (84-100%) and pigmentary changes (66,7-74%)21,25,37.  
Furthermore, the good to excellent aesthetics in this study were confirmed in previous studies and 
appear to be similar to PDT or laser ablation alone17,21,25.  
Strengths of this study consist of intra-patient comparison, histological confirmation of the efficacy 
after 12 months and evaluation of patient reported outcomes (aesthetics and treatment preference). 
A limitation is presented in the small sample size of this pilot study. According to sample size 
calculation with Sealed Envelope™38, a total sample size of 125 patients is required (power of 80%, 
δ=16,1%; α=0,025). This study did not have enough power in order to demonstrate a possible 
equivalence in efficacy, which is, however, a conditio sine qua non before one laser setting can be 
preferred to another based on secondary endpoints.  
Larger trials with longer follow-up are necessary in order to gain better understanding of the added 
value of laser-assisted PDT compared to monotherapy of PDT or ablative laser treatment in sBCC and 
BD. Moreover, further trials should search for the optimal treatment protocol and laser settings, and 
should include a subgroup analysis between sBCC and BD. While cryotherapy and 5-FU are 
inexpensive treatment regimens for NMSC, higher costs are implied in laser ablation, imiquimod or 
PDT. Consequently, laser-assisted PDT is expected to be a relatively expensive treatment. Potentially 
higher efficacy might however justify these costs in large lesions on cosmetic sensitive areas where 
self-application of topical therapy is difficult. 5-FU in vitro showed enhanced skin permeation after 
CO2 treatment39. In a clinical setting, 5-FU application under occlusion for 7 days after FL 
pretreatment is reported by Nguyen et al. to reach histological clearance in 87% of 30 sBCC and BD 
lesions40, with an overall treatment success of 79% after a mean of 15 months41. The best results 
were seen in BD. It might be interesting to conduct further exploration of laser-assisted 5-FU delivery 
as a potential cost-saving alternative.  
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Tables 
Table 1: Study protocol 
 Assesor Inclusion  Treatment  Follow-up 
    Day 1 and 14  Telephonic survey, 
day 7 and 21 
Before treatment 2, 
day 14 
3, 6 and 12 
months 
Clinical efficacy Blinded expert       x 
Histologya Pathologist x      xb 
Pain during PDT 
illumination  
Patient c   x     
Side effectsd 
Investigator (follow-up) / 
Patient (telephonic survey) 
  x  x x x 
Aesthetics 
Blinded expert / 
Patient 
      x 
Patients’ 
preference 
Patient       x 
 
a Punch biopsy 
b Only after 12 months of follow-up  
c Visual Analogue Scale (VAS) 
d Erythema, oedema, crusting, burning sensation, vesicles, hematoma, infection, pain, pigmentary changes (hypo- or 
hyperpigmentation), scarring 
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Table 2: Baseline characteristics of the 15 treated patients  
Age in years Median [range] 73  [46-87]  
Sex, n(%) 
Male 7  (47%) 
Female 8  (53%) 
Tumour, n(%) 
sBCC 9  (60%) 
BD 6  (40%) 
Localisation, n(%) 
Head- and neck area  4  (27%) 
Thorax 5  (33%) 
Arms 2  (13%) 
Legs 4  (27%) 
Fitzpatrick skin 
type, n(%) 
I 2  (13%) 
II 12  (80%) 
III 1  (7%) 
 
sBCC, superficial basal cell carcinoma; BD, Bowen’s Disease 
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Table 3: Clinical efficacy in the intention-to-treat (ITT) analysis 
Tumour  No. of 
patients 
 Follow-up 
 
 3 months 
(n=15) 
 6 months 
(n=14) 
 12 months 
(n=14) 
 CL+PDT FL+PDT  CL+PDT FL+PDT CL+PDT FL+PDT
sBCC 
 7a  CR CR  CR CR  CR CR 
 1b  PR CR  CR CR  CR CR 
 1  CR CR  PR CR  CR CR 
BD 
 3  CR CR  CR CR  CR CR 
 1a  PR PR  PR PR  CR CR 
 1  PR PR  NR PR  PR PR 
 1  CR CR  ° °  ° ° 
% CR    80,0% 86,7%  78,5% 85,7%  92,9% 92,9% 
95% CI    [-0,298;0,151]  [-0,315;0,159]  [-0,215;0,215] 
 
sBCC, superficial basal cell carcinoma; BD, Bowen’s Disease; CR – PR – NR, complete – partial – no regression; CL+PDT – 
FL+PDT, continuous – fractional ablative CO2 laser-assisted PDT; 95% CI, 95% confidence interval 
a, one patient received only PDT in the CL+PDT treatment area during the second PDT session 
b, sBCC with nodular component 
°, drop-out 
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Table 4: Side effects after treatment and during follow-up 
Side effects Treatment  Follow-up 
 
Average after treatment 1 
and 2 (n=15) 
 
Before treatment 2 
(n=15) 
3 months 
(n=15) 
 
12 months 
(n=14) 
CL+PDT FL+PDT CL+PDT FL+PDT CL+PDT FL+PDT CL+PDT FL+PDT 
Erythema 93% 87%  73% 80%  73% 73%  21% 21% 
Oedema 44% 47% 13% 7% 13% 7% n.o. n.o. 
Crusting n.o. 10%  20% 47%  13% 13%  n.o. n.o. 
Burning sensation 33% 27%  7% 7%  13% 13%  n.o. n.o. 
Pain * * 7% 7% 13% 13% n.o. n.o. 
Vesicles n.o. n.o.  n.o. 7%  13% 13%  n.o. n.o. 
Hematoma n.o. n.o.  n.o. n.o.  n.o. n.o. n.o. n.o. 
Infection n.o. n.o.  n.o. n.o.  7% 7%  n.o. n.o. 
Pigmentary changes 
(hypo- or hyperpigmentation) 
n.o. n.o. 
 
13% 20% 
 
7% 20% 
 
21% 29% 
Scarring 4% n.o.  7% n.o.  7% n.o.  n.o. n.o. 
 
CL+PDT – FL+PDT, continuous – fractional ablative CO2 laser-assisted PDT. 
n.o., no side effect observed  
* not investigated 
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Legends and figures 
 
Fig. 1 Treatment protocol and histolo
sBCC, superficial basal cell carcinoma; CL+PDT –
95% confidence interval. 1. Treatment protoco
allocated one treatment area to CL+PDT (1=A) and
allocated to receive CL+PDT and (c) FL+PDT; (d) 
photography 3 hours after MAL application, red 
clinical photograph on day 14, before initiation of
3 months, (h) 6 months and (i) 12 months. 2. Hist
biopsy of the sBCC after 12 months follow-up in th
 
 
 
  
 
gy illustrated with sBCC on the chest 
FL+PDT, continuous – fractional ablative CO2 laser-assisted PDT
l. (a) photograph before laser treatment, intra-patient rando
 the other to FL+PDT (2=F); (b) dermoscopy before treatment in
clinical photograph immediately after laser treatment; (e) fluo
light-emitting diode illumination took place immediately afterw
 the second treatment session; (g) clinical photograph after a foll
ology. (a) punch biopsy of the sBCC before treatment initiation; (
e area that received CL+PDT and (c) FL+PDT. 
; 95% CI, 
misation 
 the area 
rescence 
ards; (f) 
ow-up of 
b) punch 
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Fig. 2 Patient flow 
CL+PDT – FL+PDT, continuous – fractional ablative CO2 laser-assisted PDT; ITT, intention-to-treat 
analysis; PP, per protocol analysis. 
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Fig. 3 Pain during PDT illumination in
(a) after the first treatment session; (b) a
CL+PDT – FL+PDT, continuous – fractiona
  
 
 CL+PDT and FL+PDT on a Visual Analogue Scale 
fter the second treatment session 
l ablative CO2 laser-assisted PDT 
(VAS)  
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Fig. 4 Aesthetics after 3, 6 and 12 months follow-up in the intention-to-treat (ITT) analysis 
(a) according to patients and; (b) according to the blinded expert   
CL+PDT – FL+PDT, continuous – fractional ablative CO2 laser-assisted PDT 
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